IP Library Granted Patent US 7,842,289
Granted Patent B2
US 7,842,289 · App. 11/021,441 · Granted Nov 30, 2010

Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof

Assignee: Aduro BioTech
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,842,289
App. No.
11/021,441
Granted
Nov 30, 2010
Kind
B2
Abstract

The present invention provides recombinant nucleic acid molecules, expression cassettes, and vectors useful for expression of polypeptides, including heterologous polypeptides, such as antigens, in bacteria. Some of the recombinant nucleic acid molecules, expression cassettes and vectors comprise codon-optimized sequences encoding the polypeptides and/or signal peptides. Some of the recombinant nucleic acid molecules, expression cassettes, and expression vectors comprise sequences encoding non-Listerial and/or non-secA1 signal peptides for secretion of the polypeptides. The invention also provides bacteria comprising the nucleic acid molecules, expression cassettes, and expression vectors, as well as compositions such as vaccines comprising the bacteria. Methods of making and using the bacteria, recombinant nucleic acid molecules, and expression cassettes are also provided.

Claims (51)

1. A recombinant nucleic acid molecule, comprising:

(a) a first polynucleotide sequence encoding a signal peptide native to a Listeria monocytogenes bacterium, wherein the first polynucleotide sequence is codon-optimized to replace at least one codon of the native coding sequence of the polynucleotide with a codon that is more frequently used by Listeria monocytogenes , for expression in the Listeria monocytogenes bacterium; and

(b) a second polynucleotide sequence encoding a polypeptide heterologous to the signal peptide, wherein the second polynucleotide sequence is in the same translational reading frame as the first polynucleotide sequence, wherein the recombinant nucleic acid molecule encodes a fusion protein comprising the signal peptide and the polypeptide.

2. The recombinant nucleic acid molecule of claim 1 , wherein the signal peptide is an LLO signal peptide from Listeria monocytogenes or is a p60 signal peptide from Listeria monocytogenes.

3. An expression cassette comprising the recombinant nucleic acid molecule of claim 1 , further comprising a promoter operably linked to the first and second polynucleotide sequences of the recombinant nucleic acid molecule.

4. A recombinant Listeria monocytogenes bacterium comprising a recombinant nucleic acid molecule, wherein the recombinant nucleic acid molecule comprises:

(a) a first polynucleotide sequence encoding a signal peptide native to a Listeria monocytogenes bacterium, wherein the first polynucleotide is codon-optimized to replace at least one codon of the native coding sequence of the polynucleotide with a codon that is more frequently used by Listeria monocytogenes , for expression in the Listeria bacterium; and

(b) a second polynucleotide sequence encoding a polypeptide heterologous to the signal peptide, wherein the second polynucleotide sequence is in the same translational reading frame as the first polynucleotide sequence, wherein the recombinant nucleic acid molecule encodes a fusion protein comprising the signal peptide and the polypeptide.

5. The recombinant Listeria monocytogenes bacterium of claim 4 , which comprises an expression cassette comprising the recombinant nucleic acid molecule, wherein the expression cassette further comprises a promoter operably linked to both the first and second polynucleotide sequences of the recombinant nucleic acid molecule.

6. The recombinant Listeria monocytogenes bacterium of claim 4 , wherein the polypeptide encoded by the second polynucleotide sequence comprises an antigen selected from the group consisting of a tumor-associated antigen, a polypeptide derived from a tumor-associated antigen, an infectious disease antigen, and a polypeptide derived from an infectious disease antigen.

7. The recombinant Listeria monocytogenes bacterium of claim 6 , wherein the polypeptide encoded by the second polynucleotide sequence comprises an antigen selected from the group consisting of K-Ras, H-Ras, N-Ras, 12-K-Ras, mesothelin, PSCA, NY-ESO-1, WT-1, survivin, gp 100, PAP, proteinase 3, SPAS-1, SP-17, PAGE-4, TARP, and CEA, or comprises a polypeptide derived from an antigen selected from the group consisting of K-Ras, H-Ras, N-Ras, 12-K-Ras, mesothelin, PSCA, NY-ESO-1, WT-1, survivin, gp 100, PAP, proteinase 3, SPAS-1, SP-17, PAGE-4, TARP, and CEA.

8. The recombinant Listeria monocytogenes bacterium of claim 7 , wherein the polypeptide encoded by the second polynucleotide sequence comprises mesothelin, or an antigenic fragment or antigenic variant thereof, or comprises NY-ESO-1, or an antigenic fragment or antigenic variant thereof.

9. The recombinant Listeria monocytogenes bacterium of claim 8 , wherein the polypeptide encoded by the second polynucleotide sequence comprises human mesothelin deleted of its signal peptide and GPI linker domain.

10. The recombinant Listeria monocytogenes bacterium of claim 4 , wherein the polypeptide encoded by the second polynucleotide sequence is heterologous to the signal peptide.

11. The recombinant Listeria monocytogenes bacterium of claim 4 , wherein the signal peptide is a signal peptide selected from the group consisting of an LLO signal peptide from Listeria monocytogenes and a p60 signal peptide from Listeria monocytogenes.

12. The recombinant Listeria monocytogenes bacterium of claim 4 , which is attenuated for cell-to-cell spread, entry into non-phagocytic cells, or proliferation.

13. The recombinant Listeria monocytogenes bacterium of claim 4 , which is deficient with respect to ActA, Internalin B, or both ActA and Internalin B.

14. The recombinant Listeria monocytogenes bacterium of claim 4 , wherein the nucleic acid of the recombinant bacterium has been modified by reaction with a nucleic acid targeting compound.

15. A recombinant nucleic acid molecule, comprising:

(a) a first polynucleotide sequence encoding a signal peptide native to a Listeria monocytogenes bacterium, wherein said first polynucleotide sequence is codon-optimized to replace at least one codon of the native coding sequence of the polynucleotide with a codon that is more frequently used by Listeria monocytogenes , for expression in the Listeria monocytogenes bacterium; and

(b) a second polynucleotide sequence encoding a polypeptide heterologous to the signal peptide, wherein the second polynucleotide sequence is in the same translational reading frame as the first polynucleotide sequence, wherein the second polynucleotide sequence is codon-optimized to replace at least one codon of the native coding sequence of the polynucleotide with a codon that is more frequently used by Listeria monocytogenes , for expression in the Listeria monocytogenes bacterium, and

wherein the recombinant nucleic acid molecule encodes a fusion protein comprising the signal peptide and the polypeptide.

16. The recombinant nucleic acid molecule of claim 15 , wherein the signal peptide is a secA2 signal peptide.

17. The recombinant nucleic acid molecule of claim 15 , wherein the signal peptide is a p60 signal peptide from Listeria monocytogenes.

18. The recombinant nucleic acid molecule of claim 15 , wherein the polypeptide encoded by the second polynucleotide sequence comprises an antigen selected from the group consisting of a tumor-associated antigen, a polypeptide derived from a tumor-associated antigen, an infectious disease antigen, and a polypeptide derived from an infectious disease antigen.

19. An expression cassette comprising the recombinant nucleic acid molecule of claim 15 , further comprising a promoter operably linked to the first and second polynucleotide sequences of the recombinant nucleic acid molecule.

20. A recombinant Listeria monocytogenes bacterium comprising the recombinant nucleic acid molecule of claim 15 .

21. A recombinant Listeria monocytogenes bacterium comprising a recombinant nucleic acid molecule, wherein the recombinant nucleic acid molecule comprises:

(a) a first polynucleotide sequence encoding signal peptide native to said Listeria monocytogenes , wherein said first polynucleotide sequence is codon-optimized to replace at least one codon of the native coding sequence of the polynucleotide with a codon that is more frequently used by Listeria monocytogenes for expression in said Listeria monocytogenes ; and

(b) a second polynucleotide sequence encoding a polypeptide which is heterologous to the signal peptide or is foreign to the bacterium, or both, wherein the second polynucleotide sequence is in the same translational reading frame as the first polynucleotide sequence;

wherein the recombinant nucleic acid molecule encodes a fusion protein comprising the signal peptide and the polypeptide.

22. The recombinant Listeria monocytogenes bacterium of claim 21 , which comprises an expression cassette comprising the recombinant nucleic acid molecule, wherein the expression cassette further comprises a promoter operably linked to both the first and second polynucleotide sequences of the recombinant nucleic acid molecule.

23. The recombinant Listeria monocytogenes bacterium of claim 21 , wherein the first and second polynucleotide sequences are codon-optimized to replace at least one codon of the native coding sequence of the polynucleotide with a codon that is more frequently used by Listeria monocytogenes for expression in the Listeria monocytogenes bacterium.

24. The recombinant Listeria monocytogenes bacterium of claim 21 , wherein the signal peptide is a secA2 signal peptide.

25. The recombinant Listeria monocytogenes bacterium of claim 24 , wherein the recombinant nucleic acid molecule further comprises:

(c) a third polynucleotide sequence encoding a secA2 autolysin, or a fragment thereof, in the same translational reading frame as the first and second polynucleotide sequences, wherein the second polynucleotide sequence is positioned within the third polynucleotide sequence or between the first and third polynucleotide sequences.

26. The recombinant Listeria monocytogenes bacterium of claim 21 , wherein the polypeptide encoded by the second polynucleotide sequence comprises an antigen selected from the group consisting of a tumor-associated antigen, a polypeptide derived from a tumor-associated antigen, an infectious disease antigen, and a polypeptide derived from an infectious disease antigen.

27. The recombinant Listeria monocytogenes bacterium of claim 26 , wherein the polypeptide encoded by the second polynucleotide sequence comprises an antigen selected from the group consisting of K-Ras, H-Ras, N-Ras, 12-K-Ras, mesothelin, PSCA, NY-ESO-1, WT-1, survivin, gp 100, PAP, proteinase 3, SPAS-1, SP-17, PAGE-4, TARP, and CEA, or comprises a polypeptide derived from an antigen selected from the group consisting of K-Ras, H-Ras, N-Ras, 12-K-Ras, mesothelin, PSCA, NY-ESO-1, WT-1, survivin, gp 100, PAP, proteinase 3, SPAS-1, SP-17, PAGE-4, TARP, and CEA.

28. The recombinant Listeria monocytogenes bacterium of claim 27 , wherein the polypeptide encoded by the second polynucleotide sequence comprises mesothelin, or an antigenic fragment or antigenic variant thereof.

29. The recombinant Listeria monocytogenes bacterium of claim 28 , wherein the polypeptide encoded by the second polynucleotide sequence comprises human mesothelin deleted of its signal peptide and GPI anchor.

30. The recombinant Listeria monocytogenes bacterium of claim 21 , which is attenuated for cell-to-cell spread, entry into non-phagocytic cells, or proliferation.

31. The recombinant Listeria monocytogenes bacterium of claim 21 , which is deficient with respect to ActA, Internalin B, or both ActA and Internalin B.

32. The recombinant Listeria monocytogenes bacterium of claim 21 , wherein the nucleic acid of the recombinant bacterium has been modified by reaction with a nucleic acid targeting compound.

33. A recombinant nucleic acid molecule, comprising:

(a) a first polynucleotide sequence encoding a signal peptide native to a Listeria monocytogenes bacterium, wherein the first polynucleotide sequence is codon-optimized to replace at least one codon of the native coding sequence of the polynucleotide with a codon that is more frequently used by Listeria monocytogenes for expression in the Listeria monocytogenes bacterium;

(b) a second polynucleotide sequence encoding a secreted protein, or a fragment thereof, heterologous to the signal peptide wherein the second polynucleotide sequence is in the same translational reading frame as the first polynucleotide sequence; and

(c) a third polynucleotide sequence encoding a polypeptide heterologous to the secreted protein, or fragment thereof, wherein the third polynucleotide sequence is in the same translational reading frame as the first and second polynucleotide sequences,

wherein the recombinant nucleic acid molecule encodes a protein chimera comprising the signal peptide, the polypeptide encoded by the third polynucleotide sequence, and the secreted protein, or fragment thereof, and wherein the polypeptide encoded by the third polynucleotide sequence is fused to the secreted protein, or fragment thereof, or is positioned within the secreted protein, or fragment thereof, in the protein chimera.

34. A recombinant Listeria monocytogenes bacterium comprising the recombinant nucleic acid molecule of claim 33 .

35. The recombinant Listeria monocytogenes bacterium of claim 6 , wherein the infectious disease antigen is from a virus selected from the group consisting of a hepatitis virus, an influenza virus, and a papillomavirus.

36. The recombinant Listeria monocytogenes bacterium of claim 35 , wherein the infectious disease antigen is from a hepatitis A virus, a hepatitis B virus, or a hepatitis C virus.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2021
From: CHINOOK THERAPEUTICS, INC.
To: THE JOHNS HOPKINS UNIVERSITY
Reel/Frame 057684/0362 →
CHANGE OF NAME Recorded Oct 1, 2021
From: ADURO BIOTECH, INC.
To: CHINOOK THERAPEUTICS, INC.
Reel/Frame 057684/0448 →
BILL OF SALE AND ASSIGNMENT Recorded Jan 11, 2010
From: ANZA THERAPEUTICS, INC.
To: ADURO BIOTECH
Reel/Frame 023762/0435 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2008
From: CERUS CORPORATION
To: ANZA THERAPEUTICS, INC.
Reel/Frame 021772/0485 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2005
From: DUBENSKY, JR., THOMAS W.; PORTNOY, DANIEL A.; LUCKETT, JR., WILLIAM S.; COOK, DAVID N.
To: CERUS CORPORATION
Reel/Frame 016363/0262 →
Continuity (11)
Continuation In Part PCTUS20042388100 · Jul 23, 2004
Continuation In Part 1088359900 · Jun 30, 2004
Continuation In Part 1077361800 · Feb 6, 2004
Continuation In Part 1077379200 · Feb 6, 2004
Provisional Application 6061675000 · Oct 6, 2004
Provisional Application 6061528700 · Oct 1, 2004
Provisional Application 6059937700 · Aug 5, 2004
Provisional Application 6055674400 · Mar 26, 2004
Provisional Application 6054151500 · Feb 2, 2004
Provisional Application 6053259800 · Dec 24, 2003
Related Publication 20050249748A1 · Nov 10, 2005